Skip to main content
MGNX logo

MGNX · Macrogenics Inc · Documents

Track MGNX — free
$1.99 -0.07 (-3.17%) Q2 2024 earnings call transcript
Market Cap
$131.01M
Shares
63.91M
Volume · Nov 18 117.28K Avg daily vol (3M) 709.77K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $149.5M down 0.3% 10-K filed Mar 9, 2026 Quarterly report New FY2026 Q3 Revenue $18.67M down 64.8% 10-Q filed Nov 12, 2026 Latest results New Cash reaches $287.7 million as pipeline advances 8-K filed Nov 12, 2026 Earnings call Q2 2024 earnings call Held Aug 6, 2024
2026
Nov 13
Current report 8-K
MGC026 shows 27% response rate; cash runway through 2028

MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028.

Regulation FD disclosure
5 source passages
On November 13, 2026, MacroGenics, Inc. (the “Company”) made available an updated version of the Company’s corporate presentation on its website, which reflects updated clinical program details. MGC026 Summary: Promising Development Path in SCCHN 27% Best Overall Response in late line SCCHN 64% Disease control rate $288M Cash equiv. & marketable securities as of September 30, 2026 • Cash runway guidance through 2028 Open the document at this passage
Nov 12
Current report 8-K
Cash reaches $287.7 million as pipeline advances

MacroGenics held $287.7 million in cash, cash equivalents and marketable securities, with cash runway guidance through 2028. It reported a third-quarter net loss of $20.1 million, completed MGC028 dose escalation and dosed the first patient in MGC030’s Phase 1 study.

Financial results
4 source passages
Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028 Net loss was $20.1 million for the quarter ended September 30, 2026, compared to net income of $16.8 million for the quarter ended September 30, 2025. MGC028 is a first-in-class ADC targeting ADAM9, a protein that is overexpressed in multiple solid tumors. Phase 1 dose escalation of this molecule has been completed, and the Company has selected a lead indication. MGC030 is a first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors. Following clearance of the Investigational New Drug (IND) application, the first patient was dosed in a Phase 1 study in patients with advanced solid tumors, including urothelial, colorectal, gastric or gastroesophageal junction, esophageal and pancreatic cancers. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CDMO sale generates $87.5 million pretax gain

Macrogenics sold its CDMO Operations to Bora for a $122.5 million purchase price and received $119.6 million after adjustments, recognizing an $87.5 million pretax gain. Cash runway is expected through 2028, dependent on future partner payments and cost savings.

Revenue $18.67M ▼ 64.8% Net loss $20.08M Diluted EPS -$0.32
Read from the MD&A section
4 source passages
Effective June 30, 2026, we completed the sale of certain assets and liabilities related to our GMP manufacturing operations, including our CDMO business (the CDMO Operations) conducted at our manufacturing facility and related warehouse operations located in Frederick, Maryland to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC (collectively, Bora). Under the terms of the Bora Agreement, Bora paid us $119.6 million in July 2026, which represented the purchase price of $122.5 million net of customary adjustments, including for working capital and indebtedness, and Bora assumed responsibility for the CDMO Operations. During the nine months ended September 30, 2026, we recognized a pretax net gain on sale of $87.5 million within discontinued operations, in connection with the sale. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September 30, 2026, combined with projected and anticipated future payments from our partners, and anticipated savings from our ongoing cost-reduction initiatives, supports our cash runway through 2028. Open the document at this passage
Nov 3
Current report 8-K Events of Oct 30
Independent directors appointed as board expands

MacroGenics appointed Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors effective October 30, 2026, expanding its board from ten to eleven members.

Director or officer change, or executive pay, Regulation FD disclosure
2 source passages
On October 30, 2026, the Board of Directors (the “Board”) of MacroGenics, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee (the “Committee”) of the Board, approved an increase in the size of the Board from ten to eleven members. MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Open the document at this passage
Oct 23
Current report 8-K
Other events

MacroGenics reported interim Phase 1 MGC026 data showing a 27% best overall response rate in heavily pretreated SCCHN patients, with no treatment-related discontinuations, and plans an early 2027 front-line pembrolizumab combination cohort.

Aug 14
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $32.83M ▲ 378.0% Net income $19.52M Diluted EPS $0.31
Jul 23
Current report 8-K
Other events AI summary on its way
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $20.78M ▲ 57.5% Net loss $36.77M Diluted EPS -$0.58
Apr 8
Proxy statement DEF 14A Meeting May 19, 2026
Proxy statement AI summary on its way
Apr 8
Current report 8-K
Other events AI summary on its way
Mar 9
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $149.5M ▼ 0.3% Net loss $74.62M Diluted EPS -$1.18
Mar 2
Current report 8-K
Other events AI summary on its way
Feb 24
Current report 8-K Events of Feb 23
Other events AI summary on its way
2025
Nov 12
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $72.84M ▼ 34.2% Net income $16.82M ▼ 70.1% Diluted EPS $0.27 ▼ 70.0%
Mar 20
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $149.96M ▲ 155.3% Net loss $66.97M Diluted EPS -$1.07
2024
Nov 5
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $110.71M ▲ 964.8% Net income $56.31M ▲ 220.8% Diluted EPS $0.90 ▲ 221.4%
Showing 1–50 of 158 documents
Key facts CIK 1125345 CUSIP 556099109 13F (30d) 143 filings 127 filers Visit website Investor relations